ACIC has been a key supplier to the North American pharmaceutical market since 1973. Over the past 40 years, ACIC has evolved into a fully integrated supplier of both products and services to both the Generic and Brand Pharmaceutical companies.
We are a large volume supplier of Active Pharmaceutical Ingredients (API’s) manufactured in our global network of partner manufacturing plants. All of these facilities are FDA inspected, cGMP compliant. To complement this core activity, we have established a Generic Pharma Division to work closely with our customers and partners to bring approved ANDA’s to market.
All of our activity is supported by a long term, knowledgeable sales and customer service team and in-depth internal Regulatory department.
ACIC was the API supplier in the first Paragraph IV challenge and continues to be very active in many Paragraph IV ANDA filings today.
ACIC has helped biotech industries by investing in new process molecules. Our successes lead to the approval and launch of a new product in Japan in 2009, followed by Europe, with an expected launch in the USA in 2014.
Having anticipated legislative changes, we have been pioneers in taking advantage of the changes in the USA and Canada. As a result, ACIC has been very active, adapting to the ever changing market place to best service both our suppliers and customers.
ACIC is long time members and very active of key North American industry associations such as DCAT, GPhA and CGPA. ACIC holds a board member seat on DCAT and GPhA, as well as founding members of organizations such as and GPhA, CPhI, and CGPA.
From Molecule to Market is what we do! Working closely with our suppliers and customers, is how we do it! Our North American team looks forward to working with you and establishing a mutually beneficial relationship.
Need more information? Feel free to contact us to get the information you need.